ADDvise Group’s order intake for Q4 2018 increased by 12 percent compared to Q4 2017. Order intake for Q4 2018 was 74,8 MSEK (66,8 MSEK Q4 2017). Total order intake for 2018 amounted to 261,5 MSEK (243,4 MSEK in 2017) which is an increase by 7,5 percent compared with 2017.
- I’m pleased with the order intake during Q4. In particular, in the light of the lower costs due to achieved synergies and implemented efficiency programs. During Q4, we have taken important steps towards our financial target of 10% EBITDA margin, says Rikard Akhtarzand in a comment on the order intake.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se
Important information:
This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on January 9th 2019 at 09.00 CET.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.